NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Hoffmann-La Roche
Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, NSAIDs
Countries: Germany
This nationwide, multicenter, single arm, prospective, non-interventional study will evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use in a representative cohort of participant with moderate to severe active RA who have either responded inadequately to, or who were intolerant to previous therapy with one or more synthetic disease modifying anti-rheumatic drug (sDMARD), and for whom the physician has made the individual decision to initiate tocilizumab (subcutaneous \[SC\] or intravenous \[IV\]) as first biological disease modifying anti-rheumatic drug (DMARD) therapy according to the summary of product characteristics (SPC).
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Participants with moderate to severe active RA who have either responded inadequately to, or who were intolerant to, previous therapy with one or more sDMARDs and for whom the physician has made the individual decision to be treated with tocilizumab (SC or IV) * Current users of NSAIDs due to RA as assessed by the physician Exclusion Criteria: * Contraindications to treatment with tocilizumab as per SPC * Prior therapy with tocilizumab
- Altenburg, Germany
- Amberg, Germany
- Bad Nauheim, Germany
- Berlin, Germany
- Berlin, Germany
- Berlin, Germany
- Berlin, Germany
- Burghausen, Germany
- Dresden, Germany
- Güstrow, Germany
- Halle, Germany
- Hanover, Germany
- Heidelberg, Germany
- Magdeburg, Germany
- Mansfeld, Germany
- München, Germany
- München, Germany
- Neubrandenburg, Germany
- Neuss, Germany
- Neuss, Germany
- Offenburg, Germany
- Poppenbüttel, Germany
- Püttlingen, Germany
- Ratingen, Germany
- Saarbrücken, Germany
- Stuttgart, Germany
- Ulm, Germany